BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on DaVita (DVA), BridgeBio Pharma (BBIO) and Becton Dickinson (BDX)....

Analysts’ Opinions Are Mixed on These Healthcare Stocks: DaVita (DVA), BridgeBio Pharma (BBIO) and Becton Dickinson (BDX)

BridgeBio Pharma ( ($BBIO) ) has shared an announcement. On March 30, 2026, BridgeBio Pharma announced that it had submitted a New Drug Application...

Current Quarter	$-0.71	Next Quarter	$-0.57
Current Year	$-2.07	Next Year	$0.52
QoQ Growth	+19.7%	YoY Growth	+125.1%
3Y EPS CAGR	+9.6%	Target Price	$101.80
Consensus	Buy	Upside	+34.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BBIO	$75.48	+1.81%	1.96M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BBIO	$75.48	+1.8%	1.96M
3
4
5
6

BBIO

BBIO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get BridgeBio Pharma Inc. Data in Excel

Get BridgeBio Pharma Inc. Data in Excel